{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:25:06Z","timestamp":1789770306863,"version":"4.0.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>In immunocompetent patients, primary central nervous system lymphoma (PCNSL) typically presents with homogeneously enhancing brain lesions and high <jats:sup>18<\/jats:sup>F-FDG avidity, ranging from 2 to 5 times higher than that of healthy tissue at baseline. We present the case of a 34-year-old woman in whom PCNSL recurrence was questioned due to the appearance of mildly increased glucose metabolism (1.3 times higher than normal contralateral tissue) and FLAIR hypersignals, despite the absence of contrast enhancement or cerebrospinal fluid abnormalities. Histopathology confirmed the recurrence. This case highlights that new <jats:sup>18<\/jats:sup>F-FDG PET uptake during follow-up, even with lower avidity than baseline, should prompt concern for recurrence or residual disease in PCNSL.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005948","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T06:00:20Z","timestamp":1747116020000},"page":"1060-1061","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Mild Metabolism Increase on Posttreatment 18F-FDG PET may Indicate Recurrence of Primary CNS Lymphoma"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3993-3954","authenticated-orcid":false,"given":"Antoine","family":"Rogeau","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[{"name":"Clinical Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Mathon","sequence":"additional","affiliation":[{"name":"Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Le Garff-Tavernier","sequence":"additional","affiliation":[{"name":"Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Mokhtari","sequence":"additional","affiliation":[{"name":"Neuropathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Nichelli","sequence":"additional","affiliation":[{"name":"Neuroradiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e8s","family":"Boussen","sequence":"additional","affiliation":[{"name":"Clinical Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rozenblum","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Houillier","sequence":"additional","affiliation":[{"name":"Neurooncology, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re-Charles Foix, Assistance Publique-H\u00f4pitaux de Paris, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Kas","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"R1-20251009","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"R2-20251009","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","article-title":"Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"23","author":"Barajas","year":"2021","journal-title":"Neuro Oncol"},{"key":"R3-20251009","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1007\/s00259-023-06334-w","article-title":"[18F]FDG PET-MRI provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the BLOCAGE trial of the LOC network","volume":"50","author":"Rozenblum","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-20251009","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/neuonc\/noae029","article-title":"Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: an LOC network prospective multicentric study","volume":"26","author":"Rozenblum","year":"2024","journal-title":"Neuro Oncol"},{"key":"R5-20251009","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/RLU.0000000000005703","article-title":"Prognostic value of 18 F-FDG PET in primary central nervous system lymphoma: assessing interim metabolic response for improving patient stratification","volume":"50","author":"Song","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R6-20251009","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.3390\/cancers14174071","article-title":"Role of positron emission tomography in primary central nervous system lymphoma","volume":"14","author":"Rozenblum","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R7-20251009","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/cancers14051103","article-title":"PET imaging in neuro-oncology: an update and overview of a rapidly growing area","volume":"14","author":"Verger","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R8-20251009","first-page":"422","article-title":"Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial","volume":"19","author":"Tabouret","year":"2017","journal-title":"Neuro Oncol"},{"key":"R9-20251009","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/neuonc\/noae146","article-title":"Enhancing prognostication and treatment response evaluation in primary CNS lymphoma with 18F-FDG-PET\/CT","volume":"26","author":"Oh","year":"2024","journal-title":"Neuro Oncol"},{"key":"R10-20251009","doi-asserted-by":"crossref","first-page":"20","DOI":"10.21037\/aol-20-54","article-title":"Overcoming the blood-brain barrier in primary central nervous system lymphoma: a review on new strategies to solve an old problem","volume":"5","author":"Calimeri","year":"2021","journal-title":"Ann Lymphoma"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:03:44Z","timestamp":1760025824000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005948","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"2025-02-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}